Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
glycomimetics.com

See what CB Insights has to offer

Founded Year

2003

Stage

IPO | IPO

Total Raised

$63M

Date of IPO

1/10/2014

Market Cap

0.08B

Stock Price

1.53

Revenue

$0000 

About GlycoMimetics

GlycoMimetics is developing small molecule drugs that mimic the actions of carbohydrates using glycobiology. The company is focusing its initial efforts on therapeutics to treat inflammatory diseases such as cystic fibrosis and cancer.

GlycoMimetics Headquarter Location

101 Orchard Ridge Drive Suite 1E

Gaithersburg, Maryland, 20878,

United States

240-243-1201

Latest GlycoMimetics News

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Nov 25, 2021

November 24, 2021 08:00 PM Eastern Standard Time ROCKVILLE, Md.--( BUSINESS WIRE )--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on November 22, 2021 of a non-qualified stock option award to purchase an aggregate of 100,000 shares to one new employee. The award was granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and was made as an inducement material to the acceptance of employment with the Company by the new employee. The award, granted to Lisa DeLuca, Ph.D., the Company’s new Vice President, Regulatory Affairs, was comprised of an option to Dr. DeLuca to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) in the amount of 100,000 shares, subject to vesting as to 25% of the underlying shares on November 22, 2022 and as to the remaining underlying shares in equal monthly installments over 36 months thereafter, subject to Dr. DeLuca’s continued service through each such vesting date. The option grant has an exercise price of $1.84 per share, the closing price of the Common Stock on the date of grant, and is subject to the terms and conditions of a stock option agreement and the GlycoMimetics, Inc. Inducement Plan, which was adopted January 22, 2020 and amended on August 2, 2021, and provides for the granting of stock options and other equity awards to new employees. About GlycoMimetics, Inc. GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ wholly-owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GlycoMimetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GlycoMimetics is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

GlycoMimetics Patents

GlycoMimetics has filed 44 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/6/2017

7/27/2021

Clusters of differentiation, Immune system, Immunology, Cell biology, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/6/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/27/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Immune system, Immunology, Cell biology, Proteins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

GlycoMimetics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GlycoMimetics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.